CLDX
Celldex Therapeutics, Inc.
Set alert
- YTD
- +10.82%
- 1 year
- +15.77%
- Open
- 29.70
- Prev close
- 29.89
- Mkt cap
- 2.36B
- Vol
- 870.78K
- Avg vol
- 1.35M
- EPS
- -4.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.20
- High
- 30.12
- Forward P/E
- -7.08
- Beta
- 0.90
- Short ratio
- 4.27
- Inst. own
- 109.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.25
- 200-d avg
- 32.63
- 1y target
- 63.07
Key statistics
- Market cap
- 2.36B
- Enterprise value
- 1.63B
- Trailing P/E
- 0.00
- Forward P/E
- -7.08
- PEG ratio
- 0.00
- Price / sales
- 14960.37
- Price / book
- 3.31
- EPS (TTM)
- -4.35
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 158.00K
- Revenue growth
- -97.00%
- Free cash flow
- -133.08M
- Total cash
- 717.59M
- Total debt
- 4.90M
- Return on equity
- -43.88%
- Shares outstanding
- 78.53M
- Short % of float
- 14.51%
- 50-day average
- 34.25
- 200-day average
- 32.63
Analyst view
Consensus: strong buy
- Target (low)
- 28.00
- Target (mean)
- 63.07
- Target (high)
- 100.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -1.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -1.02 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -1.06 | -0.94 | +0.12 | +11.32% |
| May 7, 2026 | Mar 31, 2026 | -1.15 | -1.18 | -0.03 | -2.86% |
| Feb 25, 2026 | Dec 31, 2025 | -1.00 | -1.22 | -0.22 | -22.00% |
| Nov 10, 2025 | Sep 30, 2025 | -0.88 | -1.01 | -0.13 | -14.77% |
| Aug 7, 2025 | Jun 30, 2025 | -0.86 | -0.85 | +0.01 | +1.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 23, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 22, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 22, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Sep 10, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celldex.com
News
- HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target
- Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
- Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
- Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
- Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
- HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64
- Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU
- Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Your note
Sign in to keep a note on CLDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JIMENEZ FREDDY A | General Counsel | Sale | Dec 3, 2025 | 30,796 |
| MARINO JAMES J | Director | Stock Gift | Nov 17, 2024 | 2,204 |
| MARTIN SAMUEL BATES | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 1, 2026 | 32,942 |
| PEPIN RONALD A | Officer | Conversion of Exercise of derivative security | Dec 14, 2025 | 20,097 |
| WRIGHT RICHARD M | Former | Sale | Nov 12, 2025 | 20,833 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 12.15% | 9,543,671 | 287.26M | Jun 29, 2026 |
| Blackrock Inc. | 8.92% | 7,002,530 | 210.78M | Jun 29, 2026 |
| Kynam Capital Management, LP | 6.78% | 5,322,908 | 160.22M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.97% | 4,685,223 | 141.03M | Jun 29, 2026 |
| State Street Corporation | 4.97% | 3,900,427 | 117.40M | Jun 29, 2026 |
| FMR, LLC | 4.74% | 3,722,888 | 112.06M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 4.82% | 3,783,994 | 113.90M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,487,758 | 74.88M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 2,020,869 | 60.83M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.04% | 1,603,138 | 48.25M | Sep 29, 2026 |
| Vanguard Explorer Fund | 1.84% | 1,447,608 | 43.57M | Jul 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.60% | 1,254,603 | 37.76M | Jun 29, 2026 |